Vaskulárna medicína 4/2011

New possibilities in treatment of venous thromboembolism – EINSTEIN clinical program

EINSTEIN clinical program consists from three randomized trials with rivaroxaban: one for the treatment of acute deep venous thrombosis (DVT), one for the treatment of acute pulmonary embolism and one for continued treatment in patients who have received treatment for acute deep-vein thrombosis. Rivaroxaban showed noninferior efficacy compared to enoxaparin – vitamin K antagonist in the acute DVT study but in the continued treatment study rivaroxaban showed superior efficacy over placebo. Rivaroxaban, an oral factor Xa inhibitor, offers a simple, single-drug approach to the short-term and continued treatment of venous thromboembolism.

Keywords: venous thromboembolism, treatment, rivaroxaban